The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk’s popular weight-loss and ...

Novartis is cueing up a new indication in the US for its oral therapy for complement-mediated diseases – Fabhalta – after reporting new data with the drug in ultra-rare kidney disease C3 ...

They used to pay a portion for many common prescription drugs, in 2025, they pay NOTHING for any drugs until you meet your deductible! My example is for an Asthma drug which went from $30 in 2024 ...